Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis

Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis

Abstract Background Autoimmune encephalitis is a new spectrum of autoimmune disorders of the central nervous system (CNS), which are characterized by pathogenic autoantibodies against neuronal surface antigens. Clinical presentations range from acute to subacute encephalopathy with neurological and...

Full description

Bibliographic Details
Main Authors: Jonathan Wickel, Ha-Yeun Chung, Stephanie Platzer, Thomas Lehmann, Harald Prüss, Frank Leypoldt, Albrecht Günther, André Scherag, Christian Geis, on behalf of the GENERATE Study Group
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Trials
Subjects:
Autoimmune CNS disorder
Autoimmune encephalitis
Bortezomib
Autoantibody
Plasma cell
NMDA receptor
Online Access:http://link.springer.com/article/10.1186/s13063-020-04516-7

Internet

http://link.springer.com/article/10.1186/s13063-020-04516-7

Similar Items